



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 August 2026
EMA/CHMP/168733/2026
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Draft Agenda for written procedure on 17-20 August 2026

Chair: Bruno Sepodes – Vice-Chair: Outi Mäki-Ikola

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	6
1.1.	Adoption of agenda	6
1.2.	Adoption of the minutes	6
2.	Oral Explanations	6
2.1.	Pre-authorisation procedure oral explanations.....	6
2.2.	Re-examination procedure oral explanations	6
2.3.	Post-authorisation procedure oral explanations	6
2.4.	Referral procedure oral explanations	6
3.	Initial applications	6
3.1.	Initial applications; Opinions.....	6
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)	6
3.3.	Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)	6
3.4.	Update on on-going initial applications for Centralised procedure.....	7
3.5.	Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004	7
3.5.1.	KemSu - Sufentanil / Ketamine - PUMA - EMEA/H/C/006395.....	7
3.5.2.	MEPLYFFA - Arimoclomol - Orphan - EMEA/H/C/006736	7
3.5.3.	Qezzaqar - Catequentinib - Orphan - EMEA/H/C/006317	7
3.5.4.	Yartemlea - Narsoplimab - Orphan - EMEA/H/C/005247	7
3.6.	Initial applications in the decision-making phase.....	8
3.7.	Withdrawals of initial marketing authorisation application	8
3.7.1.	Apitegromab - PRIME - Orphan - EMEA/H/C/005909	8
4.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	8
4.1.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion	8
4.2.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues	8
4.3.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question	8
4.4.	Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008	8
4.5.	Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	8

5.	Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/20089	
5.1.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....	9
5.2.	Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	9
5.3.	Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	9
6.	Medical devices	9
6.1.	Ancillary medicinal substances - initial consultation	9
6.2.	Ancillary medicinal substances – post-consultation update.....	9
6.3.	Companion diagnostics - initial consultation	9
6.4.	Companion diagnostics – follow-up consultation.....	9
7.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	10
7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)10	
8.	Pre-submission issues	10
8.1.	Pre-submission issue.....	10
8.2.	Priority Medicines (PRIME).....	10
9.	Post-authorisation issues	10
9.1.	Post-authorisation issues	10
9.1.1.	Zinplava – Bezlotoxumab – EMEA/H/C/004136.....	10
10.	Referral procedures	10
10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004	10
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 .	10
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004	11
10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC	11
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....	11
10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC	11
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....	11
10.8.	Procedure under Article 107(2) of Directive 2001/83/EC	11
10.9.	Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003	11
10.10.	Procedure under Article 29 of Regulation (EC) 1901/2006.....	11

10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008	11
--------	--	----

11.	Pharmacovigilance issue	12
------------	--------------------------------	-----------

11.1.	Early Notification System	12
-------	---------------------------------	----

12.	Inspections	12
------------	--------------------	-----------

12.1.	GMP inspections	12
-------	-----------------------	----

12.2.	GCP inspections	12
-------	-----------------------	----

12.3.	Pharmacovigilance inspections	12
-------	-------------------------------------	----

12.4.	GLP inspections	12
-------	-----------------------	----

13.	Innovation Task Force	12
------------	------------------------------	-----------

13.1.	Minutes of Innovation Task Force	12
-------	--	----

13.2.	Innovation Task Force briefing meetings	12
-------	---	----

13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004	12
-------	--	----

13.4.	Nanomedicines activities	13
-------	--------------------------------	----

14.	Organisational, regulatory and methodological matters	13
------------	--	-----------

14.1.	Mandate and organisation of the CHMP	13
-------	--	----

14.2.	Coordination with EMA Scientific Committees	13
-------	---	----

14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC)	13
---------	--	----

14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	13
-------	--	----

14.4.	Cooperation within the EU regulatory network	13
-------	--	----

14.5.	Cooperation with International Regulators	13
-------	---	----

14.6.	Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee	13
-------	---	----

14.7.	CHMP work plan	13
-------	----------------------	----

14.8.	Planning and reporting	13
-------	------------------------------	----

14.9.	Others	14
-------	--------------	----

15.	Any other business	14
------------	---------------------------	-----------

15.1.	AOB topic	14
-------	-----------------	----

A.	PRE-SUBMISSION ISSUES	15
-----------	------------------------------	-----------

A.1	ELIGIBILITY REQUESTS	15
-----	----------------------------	----

A.2	Appointment of Rapporteur / Co-Rapporteur Full Applications	15
-----	---	----

B.	POST-AUTHORISATION PROCEDURES OUTCOMES	15
-----------	---	-----------

B.1.	Annual re-assessment outcomes	15
------	-------------------------------------	----

B.1.1	Annual reassessment for products authorised under exceptional circumstances	15
-------	---	----

B.2 RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES.....	15
B.2.1 Renewals of Marketing Authorisations requiring 2nd Renewal.....	15
B.2.2 Renewals of Marketing Authorisations for unlimited validity	15
B.2.3 Renewals of Conditional Marketing Authorisations.....	15
B.3 POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES	15
B.5 TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES	15
B.5.1 CHMP assessed procedures scope: Pharmaceutical aspects	16
B.5.2 CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	16
B.5.3 CHMP-PRAC assessed procedures	16
B.5.4 PRAC assessed procedures	16
B.5.5 CHMP-CAT assessed procedures	16
B.5.6 CHMP-PRAC-CAT assessed procedures	16
B.5.7 PRAC assessed ATMP procedures.....	16
B.5.8 Unclassified procedures and worksharing procedures of type I variations.....	16
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)	16
E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES	16
E.1 PMF Certification Dossiers.....	16
E.2 Timetables – starting & ongoing procedures: For information	16
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver	16
G. ANNEX G	16
G.1 Final Scientific Advice (Reports and Scientific Advice letters):	16
G.2 PRIME.....	16
Explanatory notes	18

1. Introduction

1.1. Adoption of agenda

CHMP agenda for 17-20 August 2026

1.2. Adoption of the minutes

CHMP minutes for 20-23 April 2026 meeting

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

No items

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

No items

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

No items

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

No items

3.4. Update on on-going initial applications for Centralised procedure

No item

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. KemSu - Sufentanil / Ketamine - PUMA - EMEA/H/C/006395

Proveca Pharma Limited; treatment of acute pain in children aged 1 to less than 18 years.

Scope: Re-examination request; Appointment of re-examination rapporteurs

Action: For adoption

Opinion adopted on 23.07.2026. List of Outstanding Issues adopted on 21.05.2026. List of Questions adopted on 11.12.2025.

3.5.2. MEPLYFFA - Arimoclomol - Orphan - EMEA/H/C/006736

Zevra Denmark A/S; treatment of Niemann-Pick disease type C (NPC) in patients aged 6 months and older in combination with miglustat

Scope: Re-examination request; Appointment of re-examination rapporteurs; Timetable

Action: For adoption

Opinion adopted on 23.07.2026. List of Outstanding Issues adopted on 21.05.2026. List of Questions adopted on 11.12.2025.

3.5.3. Qezzaqar - Catequentinib - Orphan - EMEA/H/C/006317

CATS Consultants GmbH; treatment of synovial sarcoma or leiomyosarcoma

Scope: Re-examination request; Appointment of re-examination rapporteurs; Timetable

Action: For adoption

Opinion adopted on 23.07.2026. List of Outstanding Issues adopted on 23.04.2026. List of Questions adopted on 13.11.2025.

3.5.4. Yartemlea - Narsoplimab - Orphan - EMEA/H/C/005247

Omeros Ireland Limited; Treatment of patients with haemopoietic stem cell transplant-associated thrombotic microangiopathy.

Scope: Appointment of re-examination rapporteurs; Timetable

Action: For adoption

Opinion adopted on 25.06.2026. List of Outstanding Issues adopted on 23.04.2026. List of Questions adopted on 13.11.2025.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Apitegromab - PRIME - Orphan - EMEA/H/C/005909

Scholar Rock Netherlands B.V.; treatment of 5q spinal muscular atrophy (SMA)

Scope: Withdrawal of marketing authorisation application

Action: For information

List of Outstanding Issues adopted on 26.03.2026, 29.01.2026. List of Questions adopted on 24.07.2025.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

No items

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

No items

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

No items

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

No items

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

No items

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

No items

8.2. Priority Medicines (PRIME)

No items

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Zinplava – Bezlotoxumab – EMEA/H/C/004136

Merck Sharp & Dohme B.V.; prevention of Clostridium difficile infection (CDI) recurrence

Rapporteur: Jan Mueller-Berghaus

Scope: Withdrawal of marketing authorisation

Action: For information

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

- 10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004**
- No items
- 10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC**
- No items
- 10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**
- No items
- 10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC**
- No items
- 10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC**
- No items
- 10.8. Procedure under Article 107(2) of Directive 2001/83/EC**
- No items
- 10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003**
- No items
- 10.10. Procedure under Article 29 of Regulation (EC) 1901/2006**
- No items
- 10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008**
- No items

11. Pharmacovigilance issue

11.1. Early Notification System

August 2026 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for August 2026.

Action: For adoption

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

No items

Annex to 17-20 August 2026 CHMP Written Procedure Agenda

Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES

A.1 ELIGIBILITY REQUESTS

A.2 Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for
August 2026: **For adoption**

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1 Annual reassessment for products authorised under exceptional circumstances

B.2 RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1 Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2 Renewals of Marketing Authorisations for unlimited validity

B.2.3 Renewals of Conditional Marketing Authorisations

B.3 POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

B.5 TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1 CHMP assessed procedures scope: Pharmaceutical aspects

B.5.2 CHMP assessed procedures scope: Non-Clinical and Clinical aspects

B.5.3 CHMP-PRAC assessed procedures

B.5.4 PRAC assessed procedures

B.5.5 CHMP-CAT assessed procedures

B.5.6 CHMP-PRAC-CAT assessed procedures

B.5.7 PRAC assessed ATMP procedures

B.5.8 Unclassified procedures and worksharing procedures of type I variations

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1 PMF Certification Dossiers

E.2 Timetables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1 Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2 PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section lists issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/